Skip to content

Clinical trials

Phase 2 Spinal Cord Injuries trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Spinal Cord Injuries Phase: Phase 2 Country / region: United States Clear all

74 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20021
20033
20041
20061
20077
20082
20105
20111
20122
20133
20142
20152
20164
20173
20183
20196
20206
20215
20221
20233
20241
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed47
Terminated9
Active, not recruiting6
Recruiting5
Unknown status4
Withdrawn2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
US Department of Veterans Affairs10
VA Office of Research and Development5
Brigham and Women's Hospital4
James J. Peters Veterans Affairs Medical Center4
Kessler Foundation4
Medstar Health Research Institute4
Northwestern University4
Spaulding Rehabilitation Hospital3
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2
Icahn School of Medicine at Mount Sinai2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Spinal Cord Injuries74
Osteoporosis8
Spinal Cord Diseases7
Bone Diseases, Metabolic6
Wounds and Injuries6
Central Nervous System Diseases5
Nervous System Diseases5
Urinary Bladder, Neurogenic5
Agnosia4
Bone Diseases4

Trials

Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.